SLC5A2 and heart failure: Additional hormonal adaptations may contribute: reductions in atrial natriuretic peptide have been observed under SGLT2 blockade in experimental heart failure and in clinical diabetes, potentially tempering natriuresis, while rises in serum sodium and osmolality can stimulate arginine vasopressin release, with its secretion during treatment correlating positively with urinary glucose and sodium excretion [125,126].